Get the Stockscreener App
1.60
5.36%
-0.08
Traws Pharma Inc stock is traded at $1.60, with a volume of 29,710.
It is down -5.36% in the last 24 hours and down -7.56% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$1.68
Open:
$1.68
24h Volume:
29,710
Relative Volume:
0.10
Market Cap:
$12.71M
Revenue:
$2.85M
Net Income/Loss:
$93.35M
P/E Ratio:
0.0664
EPS:
24.0802
Net Cash Flow:
$-19.47M
1W Performance:
-1.85%
1M Performance:
-7.56%
6M Performance:
-11.17%
1Y Performance:
-38.85%
1-Day Range:
$1.59
$1.73
1-Week Range:
$1.51
$1.73
52-Week Range:
$0.97
$3.265
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
1.59 | 13.42M | 2.85M | 93.35M | -19.47M | 24.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Initiated | H.C. Wainwright | Buy |
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
TRAW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cash per share of Traws Pharma, Inc. – FWB:0T20 - TradingView
TRAW SEC FilingsTraws Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
Traws Pharma Reports Phase 2 COVID-19 Data, Flu Program Update - MyChesCo
Traws Pharma (NASDAQ:TRAW) Trading Down 11.2% – Here’s What Happened - Defense World
Insider Sell: How much upside does Traws Pharma Inc haveTrade Entry Report & Accurate Intraday Trading Signals - baoquankhu1.vn
TRAWTraws Pharma Latest Stock News & Market Updates - Stock Titan
Traws Pharma Reports Differentiated COVID-19 and Influenza Antiviral Progress - Contagion Live
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold By Investing.com - Investing.com South Africa
Traws Pharma stock tumbles after FDA places tivoxavir marboxil on clinical hold - Investing.com
Traws Pharma Highlights Positive Ratutrelvir Phase 2 COVID-19 Data - TipRanks
Traws Pharma Stock Plunges As FDA Halts TXM IND - RTTNews
Traws Pharma completes Phase 2 ratutrelvir analysis; tivoxavir tablet shows 28-day influenza protection potential - TradingView
Traws Pharma completes analysis of ratutrelvir clinical study in Paxlovid®-eligible and ineligible Covid-19 patients - marketscreener.com
Traws Pharma Completes Analysis Of Ratutrelvir Clinical Study In Paxlovid®-Eligible And Ineligible Covid-19 Patients - TradingView
Traws Pharma Reports Completed Clinical Results of Ratutrelvir Showing Differentiated Profile Compared to PAXLOVID® with Fewer Adverse Events and No Viral Rebounds - Quiver Quantitative
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza - GlobeNewswire
Ayrton Capital LLC Reduces Stake in Traws Pharma Inc - GuruFocus
Squadron funds disclose 8.9% Traws Pharma (TRAW) ownership in 13G/A filing - Stock Titan
TRAW Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Can Traws Pharma Inc. stock rebound after recent weaknessJuly 2025 Decliners & Technical Buy Zone Confirmations - mfd.ru
How rising interest rates impact Traws Pharma Inc. stockMarket Volume Summary & Free Technical Confirmation Trade Alerts - mfd.ru
Aug EndMonth: Will RSVR outperform tech stocks2025 Key Lessons & Safe Swing Trade Setups - baoquankhu1.vn
Why Traws Pharma Inc. stock could benefit from AI revolution - mfd.ru
Published on: 2026-02-03 21:55:07 - baoquankhu1.vn
Experimental COVID Pill Shows Edge Over Paxlovid as Traws Hits Key Milestones - MyChesCo
LADENBURG THALM/SH SH Upgrades Traws Pharma (NASDAQ:TRAW) to Strong-Buy - Defense World
TRAW stock slides in volatile session – what’s the latest on its phase 2 trial for COVID-19 treatment? - MSN
Traws completes enrollment in phase 2 COVID-19 drug study By Investing.com - Investing.com Canada
Traws Pharma stock soars after completing COVID-19 treatment study By Investing.com - Investing.com South Africa
Traws Pharma stock soars after completing COVID-19 treatment study - Investing.com
TRAW Stock Slides In Volatile Session – What’s The Latest On Its Phase 2 Trial For COVID-19 Treatment? - Stocktwits
Traws Pharma (TRAW) Completes Enrollment in Phase 2 COVID-19 Stu - GuruFocus
Traws Pharma Completes Phase 2 Enrollment for COVID Candidate - TipRanks
Traws completes enrollment in phase 2 COVID-19 drug study - Investing.com
COVID drug tested in Paxlovid-ineligible patients as monthly flu pill advances - stocktitan.net
Traws targets stockpile nod as COVID drug outperforms Paxlovid in trial - MSN
Wall Street Recap: Can Traws Pharma Inc outperform under higher oil prices2025 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
Traws Pharma’s TRX-100 Phase 1 Completion: A Quiet but Key Milestone for Investors - TipRanks
Traws Targets Stockpile Nod as COVID Drug Outperforms Paxlovid in Trial - MyChesCo
Can Traws Pharma Inc. grow without dilutionOptions Play & Advanced Swing Trade Entry Alerts - bollywoodhelpline.com
Published on: 2026-01-17 06:20:37 - baoquankhu1.vn
Traws Pharma files IND for influenza treatment, updates COVID drug trial - Investing.com Nigeria
Breakout Zone: How Traws Pharma Inc stock compares to market leadersPrice Action & Risk Controlled Swing Alerts - Bộ Nội Vụ
Traws Pharma files IND for influenza treatment, updates COVID drug trial By Investing.com - Investing.com India
Traws Pharma advances flu and COVID-19 antiviral pipeline - TipRanks
Traws Pharma Files IND for Tivoxavir Marboxil and Updates Ratutrelvir Study - TradingView
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients - GlobeNewswire
Published on: 2026-01-11 07:18:09 - ulpravda.ru
New COVID pill shows promise against Paxlovid in early head-to-head trial - MSN
Fed Meeting: Is Traws Pharma Inc. stock a buy before product launches2025 Market WrapUp & Weekly Market Pulse Updates - Улправда
Traws Pharma Inc Stock (TRAW) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):